Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2019 Dec 20;132(24):3015-3017.
doi: 10.1097/CM9.0000000000000555.

Syndecan 4-c-ros oncogene 1 fusion as a mechanism of acquired resistance in epidermal growth factor receptor mutant lung adenocarcinoma

You-Cai Zhu  1 , Chun-Wei Xu  2 , Qu-Xia Zhang  2 , Wen-Xian Wang  3 , Lei Lei  3 , Wu Zhuang  4
Affiliations
Case Reports

Syndecan 4-c-ros oncogene 1 fusion as a mechanism of acquired resistance in epidermal growth factor receptor mutant lung adenocarcinoma

You-Cai Zhu et al. Chin Med J (Engl). .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Representative image of the patient. (A) CT scans of adenocarcinoma of the left lung, malignant pleural effusion. (B) CT revealed that the lung lesion and the malignant pleural effusion had grown. SDC4-ROS1 fusion is clinically actionable. (C) An Integrative Genomics Viewer snapshot of SDC4-ROS1, respectively. Soft-clipped bases reverse complement each other. (D) Follow-up CT scan of the chest showing a partial response and disappearance of the malignant pleural effusion after 1 month of crizotinib. CT: Computed tomography; SDC4-ROS1: Syndecan 4-c-ros oncogene 1.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Westover D, Zugazagoitia J, Cho BC, Lovly CM, Paz-Ares L. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol 2018; 29:i10–i19.. doi: 10.1093/annonc/mdx703. - PMC - PubMed
    1. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007; 131:1190–1203.. doi: 1016/j.cell.2007.11.025. - PubMed
    1. Gainor JF, Shaw AT. Novel targets in non-small cell lung cancer: ROS1 and RET fusions. Oncologist 2013; 18:865–875.. doi: 10.1634/theoncologist.2013-0095. - PMC - PubMed
    1. Zeng L, Yang N, Zhang Y. GOPC-ROS1 rearrangement as an acquired resistance mechanism to osimertinib and responding to crizotinib combined treatments in lung adenocarcinoma. J Thorac Oncol 2018; 13:e114–e116.. doi: 10.1016/j.jtho.2018.02.005. - PubMed
    1. Zhu Y, Xu C, Ye X, Yin M, Zhang J, Du K, et al. Lung cancer with concurrent EGFR mutation and ROS1 rearrangement: a case report and review of the literature. Onco Targets Ther 2016; 9:4301–4305.. doi: 10.2147/OTT.S109415. - PMC - PubMed

Publication types